<DOC>
	<DOCNO>NCT01703572</DOCNO>
	<brief_summary>This open-label Phase 1a dose escalation study single-agent OMP-52M51 subject relapse refractory lymphoid malignancy . Study include dose escalation phase expansion phase . Subjects assess safety , immunogenicity , pharmacokinetics , biomarkers , efficacy .</brief_summary>
	<brief_title>A Dose Escalation Study OMP-52M51 Subjects With Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Lymphoid malignancy relapse refractory two treatment FDA approve commonly use clinically . 2 . Subjects must progressive disease require therapy . Subjects candidate observation eligible . 3 . Subjects either currently consider candidate refuse potentially curative therapy include peripheral stem cell bone marrow transplant 4 . Subjects must measurable disease per disease specific criterion 5 . Must receive last chemotherapy , biologic , radiotherapy , investigational therapy least 4 week prior enrollment ; 12 week last radioimmunotherapy ; 3 month last therapy bone marrow/ peripheral stem cell transplant . 6 . Age &gt; 18 year 7 . ECOG performance status &lt; 2 8 . Normal Ejection Fraction ECHO scan 9 . Subjects must normal organ marrow function define : Absolute neutrophil count &gt; 1000/mL Platelets &gt; 75,000/mL For subject know marrow infiltration , ANC ≥500 platelet ≥30,000 Total bilirubin &lt; 1.5 X institutional upper limit normal ( ULN ) ( &lt; 2X ULN subject Gilbert 's syndrome ) AST ( SGOT ) ALT ( SGPT ) &lt; 3 X institutional ULN ( subject hepatic involvement &lt; 5 X institutional ULN ) PT/INR aPTT within 1.5 X institutional ULN Creatinine &lt; 1.5 X institutional ULN OR Creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal 10 . Women childbearing potential must prior hysterectomy negative serum pregnancy test use adequate contraception prior study entry must agree use adequate contraception study entry least 6 month discontinuation study drug . Men must also agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry study entry least 6 month discontinuation study drug . Should woman enrol study female partner man enrol study become pregnant suspect pregnant participate study within 6 month discontinuation study , inform Investigator immediately . 11 . Ability understand willingness sign write informed consent document Subjects meet follow criterion eligible participation study : 1 . Currently receive therapeutic treatment lymphoid malignancy include investigational agent 2 . Prior treatment gamma secretase inhibitor Notch 1 inhibitor 3 . Active CNS involvement , uncontrolled seizure disorder , active neurologic disease 4 . History Grade 4 allergic reaction attribute humanized human monoclonal antibody therapy 5 . Significant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 6 . Pregnant woman nurse woman 7 . Ongoing malignancy malignancy remission &lt; 3 year lymphoid malignancy include trial . Patients history know skin cancer include nonmelanotic skin cancer within past 3 year include trial . The following prior malignancy allowable irrespective occur : situ carcinoma cervix , situ ductal breast cancer , lowgrade local bladder cancer . 8 . Subjects know HIV infection 9 . Known bleed disorder coagulopathy 10 . Subjects receive heparin , warfarin , similar anticoagulant , except subject low molecular weight heparin DVT/PE prophylaxis . Note : Subjects may receive lowdose aspirin and/or nonsteroidal antiinflammatory agent . 11 . New York Heart Association Classification II , III , IV 12 . Subjects blood pressure &gt; 140/90 mmHg responsive medical therapy . Subjects take antihypertensive medication must take ≤2 medication obtain level blood pressure control . 13 . Subjects EKG evidence ischemia ≥Grade 2 ventricular arrhythmia , subject history acute myocardial infarction within 6 month , subject unstable angina . 14 . Subjects know clinically significant gastrointestinal disease include , limited , inflammatory bowel disease 15 . Subjects diarrhea time enrollment ongoing requirement anti diarrheal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>relapse refractory</keyword>
	<keyword>lymphoid malignancy</keyword>
</DOC>